Abstract
After publication of this Article concerns were raised regarding the design of the study and the robustness of its central conclusions. Post-publication peer review has confirmed that: there is insufficient justification for the grouping of the patients who belong to clinically heterogeneous cohorts with multiple different psychiatric disease presentations; the study lacks objective outcome measures; and there are concerns about the validity of the therapeutic intervention tested—specifically that Tenoten contains antibodies diluted beyond the point at which any active molecules are expected to be present and there is no molecular analysis to support the presence of molecules at these dilutions